The recently released 10K identifies the following three pending newsworthy events that should have an impact on Cardiogenics' share price:

1. IRB approval/rejection of the head-to-head study;

2. The two Material Transfer Agreements either morph into supply agreements or are terminated;

3. Merck Chemie's customers either embrace Cardiogenics' paramagnetic beads or elect to remain with their current dark beads.

IMO IRB approval (barring any surprise announcements by Cardiogenics) should occur with subjects enrolled this quarter. Time will tell if the MTA's and Merck Chemie's customers become positive or negative events; as for me, I remain positive on Cardiogenics prospects for a successful Quarter.

Ante